CAMBRIDGE, United Kingdom and PITTSBURGH, Jan. 25, 2017 /PRNewswire/ -- Sharp Edge Labs, Inc. and Cell Guidance Systems Limited today announced that they have entered into an agreement to develop and market products for exosome research. As part of the agreement, Sharp Edge Labs will make its proprietary biosensor technology available to Cell Guidance Systems for use in their exosome detection platform with a goal of providing unique tools for exosome and microvesicle research.
Cell Guidance Systems has a portfolio of microvesicle research products including Exo-Spin™ for purification, TRIFic™ for measurement, and a growing range of monoclonal antibodies. Sharp Edge Labs' biosensors have been used to create the new range of ExoFLARE™ products that allow researchers to quantify and track the movement of microvesicles.
"The importance of exosomes in intracellular communication is an area of intense research in oncology and many other disease areas as well as regenerative medicine. This agreement is part of a comprehensive strategy to build a broad portfolio of exosome research products enabling researchers to understand this critical new area of biology," said Dr. Michael Jones, CEO of Cell Guidance Systems.
"Cell Guidance is making a key set of technologies available to help researchers advance our understanding of exosome biology, a new paradigm for cell-cell communication," said Scott Sneddon, CEO of Sharp Edge Labs. "We're excited to have these tools in the hands of researchers in this important new area of biology," he added.
About Cell Guidance Systems
Cell Guidance Systems is a life science research company focused on regenerative medicine. We develop and commercialize tools and services for the life science community. We also have an early stage drug development pipeline based on PODS™, a protein stabilization technology.
For more information, visit www.cellgs.com
About Sharp Edge Labs
Sharp Edge Labs is a drug discovery company with biosensor technology for detecting cellular protein trafficking. The company uses its technology to study intracellular trafficking and defects in trafficking caused by gene mutation in a broad range of biology especially neurodegenerative disease.
For more information, visit www.sharpedgelabs.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cell-guidance-systems-limited-and-sharp-edge-labs-enter-into-exosome-technology-agreement-300396627.html